1211586-80-9

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-2-chloro-5-iodopyridine is used as a building block for the synthesis of various pharmaceuticals. Its unique halogen substituents make it a valuable intermediate in the preparation of more complex and specialized chemical compounds, contributing to the development of new drugs with improved therapeutic properties.
Used in Agrochemical Industry:
3-Bromo-2-chloro-5-iodopyridine is used as a building block in the synthesis of agrochemicals. Its unique halogen substituents enable the development of new agrochemicals with enhanced efficacy and selectivity, improving crop protection and yield.
Used in Organic Synthesis:
3-Bromo-2-chloro-5-iodopyridine is used as a versatile chemical reagent in organic synthesis. Its structural and chemical properties make it suitable for the preparation of a wide range of organic compounds, including fine chemicals, dyes, and other specialty chemicals.
Used in Materials Science:
3-Bromo-2-chloro-5-iodopyridine has potential applications in the field of materials science. Its unique halogen substituents and structural properties can be utilized in the development of new materials with specific properties, such as high-performance polymers, sensors, or other advanced materials for various applications.

Upstream product

• 130284-53-6 5-amino-3-bromo-2-chloropyridine 
• 697300-73-5 2-amino-3-bromo-5-iodopyridine 

Relevant academic research and scientific papers

Chiral Hexahalogenated 4,4′-Bipyridines

The preparation of 27 isomers of chiral hexahalogeno-4,4′-bipyridines by means of two complementary methods is described. The first one is convergent and based on the LDA-induced 4,4′-dimerization of trihalopyridines, whereas the second method is divergent and achieved through regioselective halogenation reactions of 4,4′-bipyridine-2,2′-diones. Iodine in 2,2′-positions of the 4,4′-bipyridines was introduced by a copper-catalyzed Finkelstein reaction (Buchwald procedure) performed on 2,2′-dibromo derivatives. Selected compounds of this new family of atropisomeric 4,4′-bipyridines were enantioseparated by high performance liquid chromatography on chiral stationary phases, and the absolute configurations of the separated enantiomers were assigned by using X-ray diffraction analysis. The latter revealed that various halogen bond types are responsible for crystal cohesion.

Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia

CDK9 is an essential drug target correlated to the development of acute myeloid leukemia (AML). Starting from the hit compound 10, which was discovered through a screening of our in-house compound library, the structural modifications were carried out based on the bioisosterism and scaffold hopping strategies. Consequently, compound 37 displayed the optimal CDK9 inhibitory activity with an IC50 value of 5.41 nM, which was nearly 1500-fold higher than compound 10. In addition, compound 37 exhibited significant antiproliferative activity in broad cancer cell lines. Further investigation of in vivo properties demonstrated that compound 37 could be orally administrated with an acceptable bioavailability (F = 33.7%). In MV-4-11 subcutaneous xenograft mouse model, compound 37 (7.5 mg/kg) could significantly suppress the tumor progression with a T/C value of 27.80%. Compound 37 represents a promising lead compound for the development of a novel class of CDK9 inhibitors for the treatment of acute myeloid leukemia.

Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer

A novel series of pyridin-3-amine derivatives were designed, synthesized, and evaluated as multitargeted protein kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC). Hit 1 was first disclosed by in silico screening against fibroblast